Skip to main content

Advertisement

Table 1 Clinical end points in the GOG 229 queue

From: Immunotherapy in endometrial cancer - an evolving therapeutic paradigm

GOG Trial N ORR PFS > 6mo Median PFS (mo.) Median OS (mo.)
229 N [7] 28 0 % 11 % 2.1 9.4
229 K [6] 37 9.4 % 22 % 3.3 10.1
229 I [8] 45 18.6 % 30 % 3.3 10.7
229 G* [5] 53 24.5 % 47 % 5.6 16.9
229 F* [4] 49 8.9 % 40 % 2.9 14.6
229 E [3] 56 13.5 % 40.4 % 4.2 10.5
229 J [9] 53 12.5 % 29 % 3.5 12.5
  1. *Significant Grade 3/4 adverse events were encountered on these studies preventing subsequent development of a phase 3 trial; GOG = gynecologic oncology group; ORR = overall response rate; PFS = progression free survival; OS = overall survival